ArticleAmerican journal of preventive cardiology2026
Life's Essential 8 and healthy longevity among people with and without cardiometabolic multimorbidity: A prospective study of UK Biobank.
Article in American journal of preventive cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: To investigate the impact of Life's Essential 8 (LE8) on mortality risk and life expectancy in patients with and without cardiometabolic multimorbidity (CMM). Methods: 264,675 participants from UK Biobank were categorized into low, moderate, and high cardiovascular health (CVH) levels based on LE8 score. Baseline disease status was categorized as no cardiometabolic diseases (CMD), single cardiometabolic disease (SCMD), or CMM. The Cox proportional hazards model was used to assess the risk of all-cause mortality, and the flexible parametric survival model was employed to estimate life expectancy. Results: During a median follow-up of 14.27 years, 20,335 all-cause deaths occurred. For each 10-point increase in LE8 score, the risk of all-cause mortality declined by approximately 20 % whether in groups of CMD-free, SCMD, or CMM. Compared to the CMD-free with high CVH group, the adjusted hazard ratio (HR) of all-cause mortality was 2.86 (95 % CI: 1.79-4.55) for CMM patients with high CVH, and 6.49 (95 % CI: 5.56-7.58) for CMM patients with low CVH. High CVH levels reduced CMM-related mortality risk by 66.12 %. Compared to those with low CVH, residual life expectancy at age 45 of participants with high CVH extended by 11.05 years (95 % CI: 10.97-11.14) in CMD-free group, 8.73 years (95 % CI: 8.56-8.92) in SCMD group, and 8.12 years (95 % CI: 7.59-8.64) in CMM group. Among CVH components, the tobacco/nicotine score had the greatest impact on mortality risk and life expectancy. Conclusions: Regardless of CMM statuses, higher LE8 scores were consistently associated with lower mortality risk and longer residual life expectancy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.